🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Rare Cancers

An International Study on Pediatric Patients With Rare Tumors. NCT07072143n/a1 site📍 Padova Azienda Ospedaliera di Padova A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689Phase 280 sites📍 Birmingham📍 Duarte📍 Boston Taiho Oncology, Inc. · Tests: TAS6417, CYP Cocktail, Transporter Cocktail Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients NCT07147465n/a3 sites📍 Lyon📍 Paris📍 Paris Assistance Publique - Hôpitaux de Paris Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT05168566Phase 231 sites📍 Glendale📍 Washington D.C.📍 Athens Teligene US · Tests: Sutetinib Maleate Capsule A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers. NCT04166006Phase 21 site📍 Meldola Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: Autologous DC vaccine, Interleukin-2 Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer NCT05872204Phase 212 sites📍 Liège📍 Ghent📍 Leuven Universitaire Ziekenhuizen KU Leuven · Tests: Abemaciclib, Letrozole Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers NCT06855134n/a16 sites📍 Augsburg📍 Berlin📍 Cologne German Cancer Research Center Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites📍 Scottsdale📍 Bethesda📍 Columbus Novartis Pharmaceuticals · Tests: dabrafenib, trametinib Solving Riddles Through Sequencing NCT05046444n/a1 site📍 Munich Munich Leukemia Laboratory · Tests: Next Generation Sequencing PLATFORM Study of Precision Medicine for Rare Tumors NCT04423185Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Almonertinib 110 MG, Dacomitinib 45 MG, Alectinib 150 MG, Crizotinib 250 MG, Pyrotinib 160/80 MG GROWing Up With Rare GENEtic Syndromes NCT04463316n/a1 site📍 Rotterdam dr. Laura C. G. de Graaff-Herder · Tests: Retrospective file studies Rare Embryonal Tumors of the Central Nervous System: International Registry NCT05711992n/a11 sites📍 Yerevan📍 Ottawa📍 Budapest Immune Oncology Research Institute SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access NCT02834884n/a136 sites📍 Vienna📍 Aalst📍 Antwerp European Organisation for Research and Treatment of Cancer … · Tests: RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon, 2148 MRD Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... NCT06161532Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Sacituzumab govitecan, Atezolizumab Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors NCT05868629n/a8 sites📍 Torrance📍 Denver📍 Washington D.C. Novartis Pharmaceuticals · Tests: Non-investigational Longitudinal Studies of Patient With FPDMM NCT03854318n/a1 site📍 Bethesda National Human Genome Research Institute (NHGRI) Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) NCT04498767NA13 sites📍 Anderlecht📍 Ghent📍 Wilrijk European Organisation for Research and Treatment of Cancer … · Tests: Stereotactic body radiotherapy, Palliative RT Children and Adults With Chordoma NCT03910465n/a1 site📍 Bethesda National Cancer Institute (NCI) DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations NCT06988475Phase 2, Phase 317 sites📍 Belfast📍 Birmingham📍 Bristol Cancer Research UK · Tests: Capmatinib DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers NCT05770037Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Alectinib PREcision Diagnostics in Rare genetIC Diseases and Tumors - Long Read Sequencing NCT06796751n/a1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna · Tests: DNA/RNA sequencing and bioinformatic data analysis Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification NCT05259605n/a42 sites📍 Innsbruck📍 Vienna📍 Aalst European Organisation for Research and Treatment of Cancer … · Tests: Observational The Sarcoma Biology and Outcome Project NCT04758325n/a1 site📍 Heidelberg Prof. Dr. Richard F Schlenk A Research Registry on Aggressive PitNETs NCT05974696n/a1 site📍 Lyon Hospices Civils de Lyon Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor NCT06456359Phase 24 sites📍 Heidelberg📍 Stuttgart📍 Stuttgart University Hospital Heidelberg · Tests: Signifor SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence NCT06878469NA2 sites📍 Milan📍 L’Aquila Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Tests: RehaCom Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases. NCT04880356n/a1 site📍 Milan Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Tests: collection of data DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. NCT05770544Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Entrectinib Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations NCT07185997Phase 3139 sites📍 Fullerton📍 Los Angeles📍 Orange ArriVent BioPharma, Inc. · Tests: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy